Ga onbeperkt met Magzter GOLD
Krijg onbeperkte toegang tot meer dan 9000 tijdschriften, kranten en Premium-verhalen voor slechts
Poging GOUD - Vrij
How Moderna Went From Pandemic Hero to Vaccine Victim
Mint New Delhi
|June 04, 2025
Biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in govt changes to vaccine rules
Moderna was once a darling of the first Trump administration, which went to great lengths to help the company develop its Covid-19 vaccine that protected millions of people from the virus. Now the biotech is caught in the crossfire of Trump 2.0 as vaccine-making comes under fire.
In the latest setback for Moderna, the Food and Drug Administration on Friday approved its next-generation Covid shot for a narrower population of patients than the company intended. The approval grants use of the vaccine only in older adults and people aged 12 to 64 with health risks.
Moderna is in a precarious position. The company bet big on mRNA, the underlying technology powering its vaccines, to develop shots that could treat or prevent different diseases. But after securing riches from its Covid shot, it failed to diversify its pipeline. That has become detrimental for Moderna as the Trump administration casts a critical eye on the technology and seeks to reshape the regulation, recommendations and development of vaccines.
The Department of Health and Human Services recently canceled a contract worth $766 million that was awarded to Moderna to develop mRNA-based vaccines for pandemic-level influenza including bird flu. The FDA released a new framework for approving Covid vaccines, introducing more stringent rules that require more testing. And Moderna withdrew its application with the FDA for its flu-Covid combo shot, which analysts said could have been because it fell short of the new standards.
The beleaguered company is seeking to cut costs and find a path forward postpandemic. Its shares have fallen about 35% this year because of low demand for the Covid shot and disappointing sales of its respiratory-syncytial-virus vaccine. Moderna's share price, which peaked in 2021 at $484, has dropped to prepandemic levels of about $25.
Dit verhaal komt uit de June 04, 2025-editie van Mint New Delhi.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN Mint New Delhi
Mint New Delhi
Diwali is past, but shopping season is roaring ahead
India's consumption engine appears to be humming well past the Diwali rush, with digital payments showing none of the usual post-festival fatigue.
3 mins
November 25, 2025
Mint New Delhi
AI bond flood adds to market pressure
Wall Street is straining to absorb a flood of new bonds from tech companies funding their artificial intelligence investments, adding to the recent pressure in markets.
4 mins
November 25, 2025
Mint New Delhi
TCS, Wipro US patent suits worsen IT's woes
Two of the country’s largest information technology (IT) services companies—Tata Consultancy Services Ltd and Wipro Ltd—faced fresh patent violations in the last 45 days, signalling challenges to their expansion of service offerings.
2 mins
November 25, 2025
Mint New Delhi
Auto parts firms spot hybrid gold
Auto component makers are licking their lips at the ascent of hybrids, spying a new growth engine at a time when electric vehicle (EV) sales have not measured up.
2 mins
November 25, 2025
Mint New Delhi
Micro biz has a harder time securing loan to start up
Bank lending to first-time micro-entrepreneurs has plummeted, signalling tighter credit conditions for small businesses already struggling with cash flow pressures and trade turmoil. In the first six months of the fiscal year, a key central scheme to support such lending managed to sanction just about 12% of what was sanctioned in the entire previous fiscal year, official data showed.
2 mins
November 25, 2025
Mint New Delhi
Why was a fresh approach to QCOs needed?
The government is now withdrawing the quality control orders (QCOS) issued earlier across sectors. Mint examines the original intent, the reasons for the policy reversal, and the expected national benefits from this move.
2 mins
November 25, 2025
Mint New Delhi
Inverted duty fix is next on GST agenda
GST Council to expand work on fixing anomaly at next meet
2 mins
November 25, 2025
Mint New Delhi
Page Industries scouts for missing piece of comeback puzzle
Page Industries Ltd has been struggling with muted growth.Its thrust on operational efficiencies, calibrated distribution expansion and new product launches is yet to reignite the dwindling investor faith.
1 mins
November 25, 2025
Mint New Delhi
REAL ESTATE PLAY: THE END OF INDIA’S BIGGEST TAX HACK
For years, the easiest dinner-table flex in India was a line that began with “You know what I bought that flat for?” and ended with a smug smile. Real estate wasn’t just an investment, it was a moral victory. Hold long enough and inflation would ensure you paid no to minimal tax. All thanks to indexation, a process that adjusts the cost of acquisition for inflation until the year of sale, effectively reducing your capital gains and the tax on them.
3 mins
November 25, 2025
Mint New Delhi
Independent films fight for screen space despite critical acclaim
Critically acclaimed Indian filmsthat sparkle onthe international festival circuit are finding it hard to be screened in the country even though theatresare struggling with low supply of new commercial films.
2 mins
November 25, 2025
Listen
Translate
Change font size